Previous 10 | Next 10 |
Long COVID Phase 2b/3 study may proceed under U.S. Investigational New Drug application MHRA guidance aligns on key measurements for a Long COVID registration trial, including primary endpoint and trial design elements Axcella presented at Long COVID forum co-sponsored by BIO and ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Gorodenkoff / Shutterstock.com NFT Gaming (NASDAQ: NFTG ) stock is falling on Thursday following the company’s initial public offering ( IPO ) yesterday. That IPO saw NFT Gaming list 1.69 million s...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: John Carnemolla / Shutterstock.com Ur-Energy (NYSEMKT: URG ) stock is taking a beating on Thursday after announcing a proposed public offering . According to a press release, the uranium mining company in...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Natee Photo / Shutterstock Boxed (NYSE: BOXD ) stock is gaining on Thursday despite a lack of news from the online wholesale retailer . There have been no new press releases released by Boxed that explain...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Sam Wordley / Shutterstock.com Axcella Health (NASDAQ: AXLA ) stock is on the rise Wednesday as investors react to an update from the FDA. That update has to do with the company’s Long Covid ...
Axcella Therapeutics ( NASDAQ: AXLA ) is trading ~16% higher post-market after the U.S. Food and Drug Administration cleared its Investigational New Drug ( IND ) application to begin a phase 2b/3 trial in the U.S. for AXA1125 to treat long COVID fatigue. The study design now h...
Phase 2b/3 study may proceed under U.S. Investigational New Drug application Study design now accepted by U.S. and U.K. regulatory authorities Axcella to present at Long COVID forum co-sponsored by BIO and Solve M.E. Axcella to host a conference call February 16 at 8:00 a....
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that CEO Bill Hinshaw will present a company update at SVB Securities’ 202...
Looking For Penny Stocks To Add To Your Watch List? Check The News For Clues Whether you want to trade penny stocks or find penny stocks to invest in, you need a strategy. It’s also a good idea to have a game plan should you enter a position. Starting with a watch list is usually b...
A Massachusetts-based %Biotech company is making waves Tuesday morning after the company reportedly received regulatory guidance from the U.K.’s regulatory agency for %AXA1125 as a treatment for long Covid fatigue. This exciting news have traders bidding up shares of %Axcella...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...